Strategy sharing: How to scale up the process from 10 L to 6000 ...

At the signing ceremony, Alex Li, Chairman of Intellective Bio, shared his enthusiasm for the collaboration, stating:

"This initiative represents not only a significant step forward in project execution but also a strategic alignment and integration of our respective strengths. Intellective Bio will leverage its core expertise in end-to-end development and commercial-scale manufacturing of biologics to ensure the high-quality and timely advancement of these programmes. We are proud to join forces with Kexing Biopharm to expand into international markets and deliver enhanced biologic treatment options to patients worldwide."

Mr. Zhao Yanqing, General Manager of Kexing Biopharm, also emphasised:

"With the biopharmaceutical ecosystem in China becoming increasingly mature, this collaboration will further enhance Kexing Biopharm's R&D efficiency and diversify our product pipeline, driving the growth of our global operations."

Looking ahead, Kexing Biopharm is committed to capitalising on emerging market opportunities and accelerating its global strategy to evolve into an innovative multinational biopharmaceutical company.

Supported by over 100,000 litres of operational production capacity and a highly efficient, flexible, and scalable manufacturing platform, Intellective Bio is well-positioned to ensure robust, reliable, and high-quality supply for the collaboration. This partnership further strengthens our pledge to be a trusted and capable CDMO partner in the global biopharmaceutical industry.